- France
- /
- Electronic Equipment and Components
- /
- ENXTPA:ALGID
Market Still Lacking Some Conviction On Egide S.A. (EPA:ALGID)
With a median price-to-sales (or "P/S") ratio of close to 0.4x in the Electronic industry in France, you could be forgiven for feeling indifferent about Egide S.A.'s (EPA:ALGID) P/S ratio of 0.5x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.
View our latest analysis for Egide
What Does Egide's P/S Mean For Shareholders?
Recent revenue growth for Egide has been in line with the industry. The P/S ratio is probably moderate because investors think this modest revenue performance will continue. If this is the case, then at least existing shareholders won't be losing sleep over the current share price.
Keen to find out how analysts think Egide's future stacks up against the industry? In that case, our free report is a great place to start.How Is Egide's Revenue Growth Trending?
Egide's P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.
Retrospectively, the last year delivered an exceptional 37% gain to the company's top line. Despite this strong recent growth, it's still struggling to catch up as its three-year revenue frustratingly shrank by 46% overall. Accordingly, shareholders would have felt downbeat about the medium-term rates of revenue growth.
Shifting to the future, estimates from the sole analyst covering the company suggest revenue should grow by 119% over the next year. Meanwhile, the rest of the industry is forecast to only expand by 22%, which is noticeably less attractive.
In light of this, it's curious that Egide's P/S sits in line with the majority of other companies. Apparently some shareholders are skeptical of the forecasts and have been accepting lower selling prices.
What Does Egide's P/S Mean For Investors?
Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
We've established that Egide currently trades on a lower than expected P/S since its forecasted revenue growth is higher than the wider industry. When we see a strong revenue outlook, with growth outpacing the industry, we can only assume potential uncertainty around these figures are what might be placing slight pressure on the P/S ratio. At least the risk of a price drop looks to be subdued, but investors seem to think future revenue could see some volatility.
And what about other risks? Every company has them, and we've spotted 8 warning signs for Egide (of which 4 can't be ignored!) you should know about.
If you're unsure about the strength of Egide's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
Valuation is complex, but we're here to simplify it.
Discover if Egide might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it.

Any moat with an opt-out clause for your competitors is just a fence around your own garden.
Worth looking at what previous legal action actually did to Meta rather than reaching for tobacco. The FTC's record five billion dollar privacy fine in 2019 was met with the stock rising, because it came in below fears and removed an open question. GDPR was designed to constrain large platforms and increased their share of the European ad market, because compliance cost fell hardest on small intermediaries. The FTC's antitrust case, the one that could genuinely have broken the company up, was decided in Meta's favour last November. The only thing that ever meaningfully hurt the business was Apple changing a tracking default, and Meta out-spent that too, while the ad-tech firms that could not afford to rebuild disappeared. The pattern is not that Meta survives regulation. It is that regulation keeps costing its smaller competitors more.
Andrew LeggetGreat earnings season, but are the earnings real?

About ENXTPA:ALGID
Egide
Develops, manufactures, and sells hermetic package solutions for micro-electronic and optical product applications in France, EEC outside France, the United States, Canada, and internationally.
Adequate balance sheet with low risk.